Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan
BOSTON--(BUSINESS WIRE)--Jan 12, 2023--
Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam ® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.
“We are extremely pleased to announce this exciting milestone in our first installation of a nuBeam ® system in the Asia Pacific region,” said Elizabeth Reczek, PhD, CEO of Neutron. “Japan has been at the forefront of the modern, accelerator-based era of BNCT therapy and is the world leader in clinical BNCT research. We are excited to continue this tradition of innovation through our collaboration with SKGH and are proud to offer the only system that conforms to IAEA recommendations for a neutron beam for BNCT.”
BNCT targets cancer at the cellular level by combining a tumor-targeted boron carrier drug with a neutron beam to generate DNA-damaging ionizing radiation within the tumor cell itself, while sparing surrounding normal tissues. With the potential to treat both primary tumors and local metastases in a highly targeted manner with as few as one to two treatments, BNCT represents a disruptive advance in radiation therapy for solid tumors and an exciting new tool in the oncologist’s arsenal. Neutron Therapeutics’ nuBeam ® system produces the highest neutron flux available, leading to substantially shorter treatment times and improved patient experience.
The nuBeam® neutron source is not approved for commercial or clinical use by the FDA, PMDA, EMA or other regulatory body.
About Neutron Therapeutics
Neutron Therapeutics is the leading provider of accelerator-based boron neutron capture therapy (BNCT) systems for use in targeted radiation therapy of solid tumors. Neutron Therapeutics’ flagship product, the nuBeam ® therapy platform, is a compact, in-hospital neutron source designed to replace legacy nuclear reactors for BNCT. The nuBeam ® system offers a higher neutron flux than competing systems and is the only BNCT system to adhere all IAEA-standards. www.neutrontherapeutics.com
About Shonan Kamakura General Hospital
The Tokushukai Medical Group’s Shonan Kamakura General Hospital (Executive Director: Shuzo Kobayashi M.D., Ph.D.) opened in November 1988 in Kamakura City, Kanagawa Prefecture, Japan. By practicing “no refusal” of patients such as emergency requests, the hospital has strengthened itself to meet diversifying and expanding medical needs of the society. In 2021, Advanced Medical Center Building to provide cutting-edge medical care such as regenerative medicine and radiation therapy including proton beam therapy adding to existed Tomotherapy, followed by the completion of the Emergency Medical Center and Trauma Center Building in 2022 to meet the increasing emergency medical needs of the region. Preparations are currently underway to start treatment for BNCT at the hospital. https://www.shonankamakura.or.jp/english/
View source version on businesswire.com:https://www.businesswire.com/news/home/20230112005081/en/
Elizabeth Reczek, PhD, CEO, Neutron Therapeutics,email@example.com
KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC MASSACHUSETTS
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH ONCOLOGY GENERAL HEALTH HEALTH HOSPITALS CLINICAL TRIALS
SOURCE: Neutron Therapeutics
Copyright Business Wire 2023.
PUB: 01/12/2023 09:00 AM/DISC: 01/12/2023 09:02 AM